183 related articles for article (PubMed ID: 32217039)
1. Long-term biochemical control and cause-specific survival in men with Gleason grade Group 4 and 5 prostate cancer treated with brachytherapy and external beam irradiation.
Stone NN; Skouteris V; Stock RG
Brachytherapy; 2020; 19(3):275-281. PubMed ID: 32217039
[TBL] [Abstract][Full Text] [Related]
2. I-125 or Pd-103 for brachytherapy boost in men with high-risk prostate cancer: A comparison of survival and morbidity outcomes.
Stone NN; Skouteris VM; Rosenstein BS; Stock RG
Brachytherapy; 2020; 19(5):567-573. PubMed ID: 32763013
[TBL] [Abstract][Full Text] [Related]
3. Preliminary toxicity and prostate-specific antigen response of a Phase I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer.
Stock RG; Stone NN
Brachytherapy; 2002; 1(1):2-10. PubMed ID: 15062181
[TBL] [Abstract][Full Text] [Related]
4. Is supplemental external beam radiation therapy necessary for patients with higher risk prostate cancer treated with 103Pd? Results of two prospective randomized trials.
Merrick GS; Wallner KE; Galbreath RW; Butler WM; Fiano R; Orio PF; Adamovich E
Brachytherapy; 2015; 14(5):677-85. PubMed ID: 26051802
[TBL] [Abstract][Full Text] [Related]
5. Isotope selection for patients undergoing prostate brachytherapy.
Cha CM; Potters L; Ashley R; Freeman K; Wang XH; Waldbaum R; Leibel S
Int J Radiat Oncol Biol Phys; 1999 Sep; 45(2):391-5. PubMed ID: 10487561
[TBL] [Abstract][Full Text] [Related]
6. Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: results from a single practice.
Brachman DG; Thomas T; Hilbe J; Beyer DC
Int J Radiat Oncol Biol Phys; 2000 Aug; 48(1):111-7. PubMed ID: 10924979
[TBL] [Abstract][Full Text] [Related]
7. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
8. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
Kollmeier MA; Stock RG; Stone N
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
[TBL] [Abstract][Full Text] [Related]
9. 20 Gy versus 44 Gy of supplemental external beam radiotherapy with palladium-103 for patients with greater risk disease: results of a prospective randomized trial.
Merrick GS; Wallner KE; Butler WM; Galbreath RW; Taira AV; Orio P; Adamovich E
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e449-55. PubMed ID: 22196131
[TBL] [Abstract][Full Text] [Related]
10. 20 Gy versus 44 Gy supplemental beam radiation with Pd-103 prostate brachytherapy: preliminary biochemical outcomes from a prospective randomized multi-center trial.
Wallner K; Merrick G; True L; Sherertz T; Sutlief S; Cavanagh W; Butler W
Radiother Oncol; 2005 Jun; 75(3):307-10. PubMed ID: 16086912
[TBL] [Abstract][Full Text] [Related]
11. Stage T3b prostate cancer diagnosed by seminal vesicle biopsy and treated with neoadjuvant hormone therapy, permanent brachytherapy and external beam radiotherapy.
Stone NN; Stock RG
BJU Int; 2019 Feb; 123(2):277-283. PubMed ID: 29956864
[TBL] [Abstract][Full Text] [Related]
12. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
[TBL] [Abstract][Full Text] [Related]
13. Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy.
Stone NN; Potters L; Davis BJ; Ciezki JP; Zelefsky MJ; Roach M; Shinohara K; Fearn PA; Kattan MW; Stock RG
Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):341-6. PubMed ID: 18597953
[TBL] [Abstract][Full Text] [Related]
14. Role of isotope selection in long-term outcomes in patients with intermediate-risk prostate cancer treated with a combination of external beam radiotherapy and low-dose-rate interstitial brachytherapy.
Wernicke AG; Shamis M; Yan W; Trichter S; Sabbas AM; Goltser Y; Christos PJ; Brennan JS; Parashar B; Nori D
Urology; 2012 May; 79(5):1098-104. PubMed ID: 22546388
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy improves prostate cancer survival for patients with potentially lethal prostate cancer: The impact of Gleason pattern 5.
Liss AL; Abu-Isa EI; Jawad MS; Feng FY; Vance SM; Winfield RJ; Narayana V; Sandler HM; McLaughlin PW; Hamstra DA
Brachytherapy; 2015; 14(4):502-10. PubMed ID: 25911994
[TBL] [Abstract][Full Text] [Related]
16. Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial.
Martinez AA; Kestin LL; Stromberg JS; Gonzalez JA; Wallace M; Gustafson GS; Edmundson GK; Spencer W; Vicini FA
Int J Radiat Oncol Biol Phys; 2000 May; 47(2):343-52. PubMed ID: 10802358
[TBL] [Abstract][Full Text] [Related]
17. Comparison of high-dose proton radiotherapy and brachytherapy in localized prostate cancer: a case-matched analysis.
Coen JJ; Zietman AL; Rossi CJ; Grocela JA; Efstathiou JA; Yan Y; Shipley WU
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):e25-31. PubMed ID: 21470787
[TBL] [Abstract][Full Text] [Related]
18. Twelve-month prostate-specific antigen values and perineural invasion as strong independent prognostic variables of long-term biochemical outcome after prostate seed brachytherapy.
Ding W; Lee J; Chamberlain D; Cunningham J; Yang L; Tay J
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):962-7. PubMed ID: 22494584
[TBL] [Abstract][Full Text] [Related]
19. Prostatic acid phosphatase adversely affects cause-specific survival in patients with intermediate to high-risk prostate cancer treated with brachytherapy.
Fang LC; Dattoli M; Taira A; True L; Sorace R; Wallner K
Urology; 2008 Jan; 71(1):146-50. PubMed ID: 18242384
[TBL] [Abstract][Full Text] [Related]
20. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.
Ko EC; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):600-7. PubMed ID: 21985944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
